Abstract
Introduction: The anti-amyloid drug donanemab is approved In the United States and Europe for treatment of early symptomatic Alzheimer’s disease (mild dementia) in adults with confirmed amyloid pathology. Evolocumab was also reported to lower the risks of heart attacks and Alzheimer. In view of longevity and continued early Alzheimer recognition, we planned to compare costs of donanemab and evolocumab with other drug classes.
Methods: Drug costs were obtained from Google search and yearly cost calculated.
Results: Yearly costs of evolocumab were $6,840. Donanemab was more expensive at $32,000. Pembrolizumab was $160,00, durvalumab $115,000, Osimertinib $100,000, semaglutide $12,000, proposed 9-month ivonescimab $188,000.
Conclusions: Donanemab $32,000 yearly cost was higher than evolocumab at $6,840. Both drugs were reasonably priced as compared with other classes. Considering longevity, the overall worldwide Alzheimer future management would be too costly to be affordable.